Skip to main content
. 2010 Aug 30;89(1):214–224. doi: 10.1093/cvr/cvq275

Figure 1.

Figure 1

Vascular effects of LY83583 are via generation of reactive oxygen species. (A, bar chart) Effects of LY83583 (1 μmol/L: 1-LY, 10 μmol/L: 10-LY) on L-012 luminescence, taken as a measure of reactive oxygen species production in mesenteric artery (MA, n = 9–10), and pulmonary artery (PA, n = 6–21). *P < 0.05 for LY83583 vs. control (artery without LY83583). †P < 0.05 for dicoumarol (Dic, 10 μmol/L) vs. 10 μmol/L LY83583. (B) Measurement of tension (mN) in PA (left) and MA (right) pre-constricted for 10–15 min with U46619 (range: 100–200 nmol/L) and 1 mmol/L l-NAME before application of 10 μmol/L LY83583 for a further 15 min alone (PA n = 4, MA n = 12), or in the presence of catalase (200 U/mL, PA n = 4, MA n = 7) or superoxide dismutase (SOD) and catalase (200 U/mL each, PA n = 4, MA n = 9). Bar charts: Constriction in PA (left) and MA (right) measured at 15 min before and after application of LY83583, normalized to constriction induced by 80 mmol/L K+. Asterisk denotes significant constriction (PA) or relaxation (MA) in response to LY83583 (P < 0.01).